AchtyesE, SimmonsA, SkabeevA, LevyN, JiangY, MarcyP, WeidenPJ: Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: A survey of patients living with schizophrenia. BMC Psychiatry, 18:292, 2018.
2.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27:596–601, 2004.
CakirB, Yalin SapmazS, KandemirH. Use ofAntipsychotics: The experiences, views, and monitoring practices of child and adolescent psychiatrists in Turkey. J Child Adolesc Psychopharmacol, 31:73–78, 2021.
5.
CoccurelloR, MolesA: Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design. Pharmacol Ther, 127:210–251, 2010.
6.
CohenE, HallM, LopertR, BruenB, ChamberlainLJ, BardachN, GedneyJ, ZimaBT, BerryJG: High-expenditure pharmaceutical use among children in medicaid. Pediatrics, 140:e20171095, 2017.
7.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773, 2009.
8.
CoustalsN, MenardML, CohenD: Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol, 31:4–32, 2021.
9.
CouturierJ, IsserlinL, SpettigueW, NorrisM: Psychotropic medication for children and adolescents with eating disorders. Child Adolesc Psychiatr Clin N Am, 28:583–592, 2019.
10.
HenshallC, CiprianiA, RuvoloD, MacdonaldO, WoltersL, KoychevI: Implementing a digital clinical decision support tool for side effects of antipsychotics: A focus group study. Evid Based Mental Health, 22:56–60, 2019.
11.
HoJ, PanagiotopoulosC, McCrindleB, GrisaruS, PringsheimT: Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health, 16:575–580, 2011.
KaraI, PennerM: Impact of Antipsychotic Guidelines on Laboratory Monitoring in Children with Neurodevelopmental Disorders. J Child Adolesc Psychopharmacol, 31:79–83, 2021.
14.
KealeyE, ScholleSH, ByronSC, HoagwoodK, Leckman-WestinE, KelleherK, FinnertyM: Quality concerns in antipsychotic prescribing for youth: A review of treatment guidelines. Acad Pediatr 14(5, Suppl):S68–S75, 2014.
15.
LenzeEJ, NicolGE, BarbourDL, KannampallilT, WongAWK, PiccirilloJ, DrysdaleAT, SylvesterCM, HaddadR, MillerJP, LowCA, LenzeSN, FreedlandKE, RodebaughTL: Precision clinical trials: A framework for getting to precision medicine for neurobehavioural disorders. J Psychiatry Neurosci, 46:E97–E110, 2021.
16.
MarufAA, SteinK, ArnoldPD, AitchisonKJ, MullerDJ, BousmanC: CYP2D6 and antipsychotic treatment outcomes in children and youth: a systematic review. J Child Adolesc Psychopharmacol, 31:33–45, 2021.
17.
MelamedOC, LaChanceLR, O'NeillBG, RodakT, TaylorVH: Interventions to Improve Metabolic Risk Screening Among Children and Adolescents on Antipsychotic Medication: A Systematic Review. J Child Adolesc Psychopharmacol, 31:63–72, 2021.
18.
NicolGE, YinglingMD, FlavinKS, SchweigerJA, PattersonBW, SchechtmanKB, NewcomerJW: Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: A Randomized Clinical Trial. JAMA Psychiatry, 75:788–796, 2018.
19.
OlfsonM, BlancoC, LiuL, MorenoC, LajeG: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry, 63:679–685, 2006.
20.
PeckRW: Precision medicine is not just genomics: The right dose for every patient. Annu Rev Pharmacol Toxicol, 58:105–122, 2018.
21.
PetersonBS: Editorial: Biomarkers in precision medicine for mental illnesses. J Child Psychol Psychiatry, 61:1279–1281, 2020.
22.
PringsheimT, PanagiotopoulosC, DavidsonJ, HoJ: Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health, 16:581–589, 2011.
23.
RiceTR, WaltherA: Male-specific metabolic considerations concerning the prescription of second-generation antipsychotics to adolescents. J Child Adolesc Psychopharmacol, 31:53–55, 2021.
24.
RoelandEJ, BohlkeK, BaracosVE, et al.: Management of cancer cachexia: ASCO Guideline. J Clin Oncol, 38:2438–2453, 2020.
25.
SchoemakersRJ, van KesterenC, van RosmalenJ, EussenM, DielemanHG, Beex-OosterhuisMM: No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. J Child Adolesc Psychopharmacol, 29:192–196, 2019.
26.
SikichL, FrazierJA, McClellanJ, FindlingRL, VitielloB, RitzL, AmblerD, PugliaM, MaloneyAE, MichaelE, De JongS, SlifkaK, NoyesN, HlastalaS, PiersonL, McNamaraNK, Delporto-BedoyaD, AndersonR, HamerRM, LiebermanJA: Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry, 165:1420–1431, 2008.
27.
TaylorJH, AppelS, EliM, Alexander-BlochA, MaayanL, GurRE, BlochMH: Time to clinical response in the treatment of early onset schizophrenia spectrum disorders study. J Child Adolesc Psychopharmacol, 31:46–52, 2021.
28.
ZhangJP, LenczT, ZhangRX, NittaM, MaayanL, JohnM, RobinsonDG, FleischhackerWW, KahnRS, OphoffRA, KaneJM, MalhotraAK, CorrellCU: Pharmacogenetic Associations of Antipsychotic drug-related weight gain: A systematic review and meta-analysis. Schizophr Bull, 42:1418–1437, 2016.
